Publication Name	World Journal of Gastroenterology
Manuscript ID	825
Country	United States

Received	2012-10-17 10:59
Peer-Review Started	2012-10-17 15:01
To Make the First Decision	2012-11-14 10:36
Return for Revision	2013-01-31 09:27
Revised
Second Decision	2013-03-15 18:04
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-03-15 23:19
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-04-20 13:28
Publish the Manuscript Online	2013-05-07 10:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review
Manuscript Source	Invited Manuscript
All Author List	Renée M Marchioni and Gary R Lichtenstein
Funding Agency and Grant Number
Corresponding Author	Gary R Lichtenstein, MD, Division of Gastroenterology, Hospital of the University of Pennsylvania, GI Administration Offices, 9th Floor Penn Tower, One Convention Avenue, PA 19104, United States. grl@uphs.upenn.edu
Key Words	Tumor necrosis factor-α inhibitors; Pregnancy; Congenital abnormalities; Safety; Infliximab; Adalimumab; Certolizumab
Core Tip	A systematic literature review was performed to identify all human studies with birth outcomes data after maternal exposure to infliximab, adalimumab, or certolizumab pegol within 3 mo of conception or during any trimester of pregnancy. After systematic literature review investigating tumor necrosis factor-α inhibitor therapy and fetal risk, there is insufficient evidence to prove absolute safety for the use of biologics (specifically infliximab, adalimumab, and certolizumab pegol) during pregnancy.
Publish Date	2013-05-07 10:53
Citation	Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602
URL	http://www.wjgnet.com/1007-9327/full/v19/i17/2591.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i17.2591

Full Article (PDF)	WJG-19-2591.pdf
Manuscript File	825-Review.docx
Answering Reviewers	825-Answering reviewers.pdf
Copyright License Agreement	825-Copyright assignment.pdf
Peer-review Report	825-Peer reviews.docx
Scientific Editor Work List	825-Scientific editor work list.doc